Summary of official drug instructions for nirogacestat

Nirogacestat (nirogacestat) is an innovative oral inhibitor targeting gamma-secretase. It has been approved in many countries for the treatment of progressive desmoid tumors (Desmoid Tumor). It is especially suitable for patients who cannot be surgically removed or have recurrence or local invasion. Its official drug insert details the pharmacological effects, scope of indications, recommended dosage, adverse reactions, safety monitoring, contraindications and other contents of the drug, which has important guiding significance for rational clinical use and patient safety management. The following is an analysis of the important information contained in the manual:

1. Basic information and mechanism of action of drugs

Nilogastat is aγ-secretase inhibitor. γ-secretase is a transmembrane protein complex that participates in the activation of multiple cell signaling pathways, especially closely related to Notch signaling. In desmoid tumors, excessive activation of the Notch pathway is directly related to abnormal proliferation of tumor cells. Nirogacestat controls the division and expansion of tumor cells from the root by inhibiting γ-secretase, thereby inhibiting the Notch signaling pathway. It is a treatment with a clear mechanism and strong targeting.

2. Description of approved indications

According to the instructions,Nirogacestat is suitable for the treatment of adult patients with advanced desmoid tumors who require systemic treatment. Although this type of tumor is benign, it is highly locally invasive, prone to recurrence, and carries a high risk of surgical resection. For individuals who are unable to undergo surgical treatment or who have frequent recurrences after surgery, Nirogacestat provides a non-invasive, targeted treatment option that meets the clinical needs of such patients for long-term control of tumor progression.

3. Recommended dosage and usage

The standard usage recommended by the instructions is: take orally twice a day, 150 mg each time Medication should be continued under the guidance of a physician until disease progression or unacceptable adverse reactions occur. The drug can be taken on an empty stomach or with a meal, but care should be taken at relatively even intervals every day to ensure stable blood drug concentration. If moderate or severe adverse reactions occur, the doctor can suspend, reduce the dose or terminate the medication according to the situation.

4. Overview of common adverse reactions

According to the instructions, adverse reactions mainly include but are not limited to:

Gastrointestinal symptoms: such as diarrhea, nausea, constipation;

Endocrine and metabolic abnormalities: Especially female patients may have ovarian dysfunction, including menstrual disorders and amenorrhea;

Fatigue and loss of appetite: Some patients will feel weak and slightly lose weight in the early stages of taking the drug;

Electrolyte disorders: such as hypophosphatemia, hypocalcemia, etc., require regular monitoring.

Most adverse reactions are reversible and can be gradually alleviated after dose adjustment or symptomatic treatment. Therefore, a good monitoring and follow-up mechanism should be established.

5. Special groups and taboos

Pregnant and lactating women: This drug may cause risks to the fetus or infant. It is contraindicated during pregnancy and feeding should be suspended during lactation.

Women of childbearing age: It is recommended to take reliable contraceptive measures during and after treatment to avoid the potential impact of the drug on fetal development.

Patients with hepatic and renal insufficiency: There are currently limited data, so it should be used with caution and relevant organ functions should be closely monitored during treatment.

People who are allergic to the active ingredients or excipients of the drug should not use this product.

6. Drug storage and prescription management

This drug is a prescription drug and must be used under the guidance of an experienced oncologist or physician. It is recommended to store in a dry environment at room temperature, away from high temperature or humidity, and out of reach of children.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html